Literature DB >> 8826857

Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.

M E Harper1, E Glynne-Jones, L Goddard, V J Thurston, K Griffiths.   

Abstract

Vascular endothelial growth factor (VEGF) expression was examined by immunohistochemistry in 45 prostatic carcinoma specimens and ten benign prostatic tumours (BPH). The majority of carcinoma specimens exhibited cytoplasmic staining for VEGF and showed a trend of increasing expression with dedifferentiation (2p = 0.003). Immunoreactive VEGF was also seen in the prostatic carcinoma cell lines, the order of staining intensity was PC3 > DU145 > LNCaP. Intense granular cytoplasmic staining for VEGF was observed in neuroendocrine-like cells which were seen focally in many of the prostatic specimens. Consecutive sections were incubated with a chromogranin A antibody to confirm the neuroendocrine phenotype of these cells. A significant correlation (P < 0.0001) between the total number of intensely stained VEGF-positive cells and chromogranin A-positive cells was found. A subpopulation of neuroendocrine-like cells also showed intense immunoreactivity for transforming growth factor alpha (TGF-alpha). A correlation was observed (2p = 0.0092) between the intensity of VEGF and TGF-alpha immunostaining in carcinoma cells which were not of neuroendocrine differentiation. The presence of these two angiogenic factors may aid the neovascularisation of carcinomas and their increased expression in tumour-associated neuroendocrine cells may contribute to a more aggressive phenotype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8826857      PMCID: PMC2074752          DOI: 10.1038/bjc.1996.456

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  57 in total

1.  Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP.

Authors:  Y J Bang; F Pirnia; W G Fang; W K Kang; O Sartor; L Whitesell; M J Ha; M Tsokos; M D Sheahan; P Nguyen; W T Niklinski; C E Myers; J B Trepel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

2.  Angiostatic activities of medroxyprogesterone acetate and its analogues.

Authors:  T Yamamoto; N Terada; Y Nishizawa; V Petrow
Journal:  Int J Cancer       Date:  1994-02-01       Impact factor: 7.396

3.  Prognostic relevance of transforming growth factor alpha (TGF-alpha) and tumor necrosis factor alpha (TNF-alpha) detected in breast cancer tissues by immunohistochemistry.

Authors:  Z Bebök; B Márkus; P Németh
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma.

Authors:  S Vesalainen; P Lipponen; M Talja; E Alhava; K Syrjänen
Journal:  Anticancer Res       Date:  1994 Mar-Apr       Impact factor: 2.480

Review 5.  Vascular endothelial growth factor and its receptors.

Authors:  G Neufeld; S Tessler; H Gitay-Goren; T Cohen; B Z Levi
Journal:  Prog Growth Factor Res       Date:  1994

6.  Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate.

Authors:  K W Schmid; B Helpap; M Tötsch; R Kirchmair; B Dockhorn-Dworniczak; W Böcker; R Fischer-Colbrie
Journal:  Histopathology       Date:  1994-03       Impact factor: 5.087

7.  Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

Authors:  A Takahashi; H Sasaki; S J Kim; K Tobisu; T Kakizoe; T Tsukamoto; Y Kumamoto; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

8.  Quantitative analysis of vascular endothelial growth factor in primary breast cancer.

Authors:  M Toi; S Kondo; H Suzuki; Y Yamamoto; K Inada; T Imazawa; T Taniguchi; T Tominaga
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

9.  Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists.

Authors:  M Abdul; P E Anezinis; C J Logothetis; N M Hoosein
Journal:  Anticancer Res       Date:  1994 May-Jun       Impact factor: 2.480

10.  Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease.

Authors:  S Y Anandappa; J H Winstanley; S Leinster; B Green; P S Rudland; R Barraclough
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

View more
  19 in total

1.  Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis.

Authors:  H Chaib; E K Cockrell; M A Rubin; J A Macoska
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

2.  Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.

Authors:  Jiaoti Huang; Jorge L Yao; Li Zhang; Patricia A Bourne; Andrew M Quinn; P Anthony di Sant'Agnese; Jay E Reeder
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

3.  Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells.

Authors:  M Goh; F Chen; M T Paulsen; A M Yeager; E S Dyer; M Ljungman
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

Review 4.  Molecular pathology of prostate cancer.

Authors:  C Hughes; A Murphy; C Martin; O Sheils; J O'Leary
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

5.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

6.  Angiogenesis and lymphangiogenesis of gastric cancer.

Authors:  Yasuhiko Kitadai
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

Review 7.  Angiogenesis inhibitors in the treatment of prostate cancer.

Authors:  Clara Hwang; Elisabeth I Heath
Journal:  J Hematol Oncol       Date:  2010-08-02       Impact factor: 17.388

8.  The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates.

Authors:  Wayne A Fritz; Tien-Min Lin; Richard E Peterson
Journal:  Carcinogenesis       Date:  2008-03-20       Impact factor: 4.944

9.  Role of vascular endothelial growth factor in clinically localized prostate cancer treated with radiation therapy.

Authors:  Eda Yirmibeşoğlu Erkal; Hüseyin Bora; Merih Tepeoğlu; Müge Akmansu
Journal:  Balkan Med J       Date:  2014-03-01       Impact factor: 2.021

10.  The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice.

Authors:  Wayne A Fritz; Tien-Min Lin; Stephen Safe; Robert W Moore; Richard E Peterson
Journal:  Biochem Pharmacol       Date:  2008-12-31       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.